Email not displaying correctly?
[~ViewInBrowser~]View it in your browser[~EndViewInBrowser~]
Stevia First gaining investor interest

Investors in Stevia First Corp. (STVF) may soon have reason to smile as the company appears to be moving from a start-up development stage company into a solid revenue producer. The timing may prove financially rewarding for the company and investors as the sugar substitute market continues to steadily increase and is estimated to grow to $13.7 billion by 2018, with high intensity sweeteners (HIS) like stevia, a zero calorie natural product, showing the largest percentage increase.
Stevia First Corp. has developed a novel approach to producing stevia based on a microbial fermentation process that should meet the demands of both the retail consumer and the giant food manufacturers by developing a consistent supply line of quality stevia at a more-than-competitive price.
As an investor, what I like is when a company can sell a product that is superior to its competition. The fermentation method is estimated to reduce the cost of producing stevia up to 70% below the conventional farming method while ensuring a superior taste profile, which to me makes it a superior product. If Stevia First can develop a secure supply line of a better tasting stevia at a far lower cost than what’s on the market today, it should be able to attract a number of large food and beverage manufacturers, especially from the soda industry.
Coke and Cargill’s stevia partnership
The anti-sugar, anti-artificial sweetener backlash has hit the soda industry hard. Diet soft drink sales have dropped in each of the past six years. Last year sales declined 3.4%, an even greater percentage than the 2.5% drop in 2011. Giant bottlers like Coca-Cola (KO) and PepsiCo. (PEP) are taking note and are now investing their dollars in stevia as consumers are looking for a way to cut sugar consumption while shying away from artificially sweetened beverages.

Stevia First launches new resource site

See More

Growth Circle top prospect

See More

"Stevia First has over 1,000 acres in the agriculturally rich Central Valley of California,"

Last year Coca-Cola launched its first stevia/sugar-based cola, Coke Life, using its Truvia brand stevia developed in partnership with the giant food processor and marketer Cargill. Both Stevia First and Cargill have separately completed pilot stages of their fermentation method, and are both expecting to move into production on a commercial level in the near future.Stevia First Corp taps into the organic market
Today organic food is big business; sales in the US have grown 350% from 2004 to 2014, and still gaining ground.
Stevia First will be the only US grower and producer of organic stevia on a commercial level. Stevia First sees tremendous potential catering to the organic market and has a vision of converting under-producing vegetable and tree crop acreage to commercial stevia leaf production.
Though I don’t see the organic stevia market nearly as lucrative as the fermentation-based stevia market, growing organic stevia has potential to drive the value of the company and the stock up considerably.
Conclusion
The World Health Organization earlier estimated that stevia could eventually replace 20-30% of all dietary sweeteners. Considering the global sweetener market is expected to rise to $97.2 billion by 2017, stevia would have the potential to one day reach between $15.5 billion and $23.25 billion annually. Pure Circle’s CFO has stated “It was a breakthrough year (2014) for stevia by any category. From size of the brand, the range of categories and countries, it was certainly a step change in the stevia market.”
That tells me that there is great potential for Stevia First Corp’s stock to rise significantly.

Morgan Stanley: The Economic Impact of Sugar

See More

The right company, at the right time

See More

Words From the CEO

See More

All statements and opinions expressed herein are those of the editors and staff of Mobius Biotechnology and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. No information contained in our website, e-mail communications or our publications should be considered as a so-licitation to purchase or sell any of the securities mentioned. Mobius Bio-technology, its principals or employees are not registered investment advi-sors or a registered securities broker dealer. We do not undertake or repre-sent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties. Readers are encouraged to do their own due diligence before investing in any securities mentioned in this newsletter. Investing in securities is specu-lative and carries a high degree of risk. We encourage our readers to invest carefully and read the investor infor-mation available at the web sites of the Securities and Exchange Commis-sion at http://www.sec.gov and/or the National Association of Securities Dealers at http://www.finra.org. We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The Mobius Biotechnology Newsletter is an electronic publication commit-ted to providing our readers with useful information on publicly traded com-panies. The newsletter sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing infor-mation and opinion about the company and the trading market for their se-curities. Principals of the newsletter may also purchase or sell securities of the companies in the open market from time to time. Mobius Biotechnology has received compensation of five thousand dollars cash from Stevia First for the distribution of this newsletter, and should be considered in making an investment decision regarding companies mentioned in this newsletter. The information found in this newsletter is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the expressed, written consent of Mobius Biotechnology.

Email Marketing